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Infection with equid herpesvirus type 1 (EHV-1) leads to respiratory disease, abortion, and neurologic disorders in
horses. Molecular epidemiology studies have demonstrated that a single nucleotide polymorphism resulting in an
amino acid variation of the EHV-1 DNA polymerase (N752/D752) is significantly associated with the neuropathogenic
potential of naturally occurring strains. To test the hypothesis that this single amino acid exchange by itself influences
neuropathogenicity, we generated recombinant viruses with differing polymerase sequences. Here we show that the
N752 mutant virus caused no neurologic signs in the natural host, while the D752 virus was able to cause inflammation
of the central nervous system and ataxia. Neurologic disease induced by the D752 virus was concomitant with
significantly increased levels of viremia (p ¼ 0.01), but the magnitude of virus shedding from the nasal mucosa was
similar between the N752 and D752 viruses. Both viruses replicated with similar kinetics in fibroblasts and epithelial
cells, but exhibited differences in leukocyte tropism. Last, we observed a significant increase (p , 0.001) in sensitivity
of the N752 mutant to aphidicolin, a drug targeting the viral polymerase. Our results demonstrate that a single amino
acid variation in a herpesvirus enzyme can influence neuropathogenic potential without having a major effect on virus
shedding from infected animals, which is important for horizontal spread in a population. This observation is very
interesting from an evolutionary standpoint and is consistent with data indicating that the N752 DNA pol genotype is
predominant in the EHV-1 population, suggesting that decreased viral pathogenicity in the natural host might not be
at the expense of less efficient inter-individual transmission.
Citation:GoodmanLB,LoregianA,PerkinsGA,NugentJ,BucklesEL,etal.(2007)Apointmutationinaherpesviruspolymerasedeterminesneuropathogenicity.PLoSPathog3(11):
e160. doi:10.1371/journal.ppat.0030160
Introduction
Equid herpesvirus type 1 (EHV-1) is an aerosol-transmitted
alphaherpesvirus, which causes rhinopneumonitis, abortion,
andparalysis.Devastatingoutbreaksoftheparalyticformofthe
disease occurred recently worldwide, resulting in its classiﬁca-
tionasa potentially emergingdiseaseby theUSDepartmentof
Agriculture [1]. A single nucleotide polymorphism in the
catalytic subunit (Pol) of the viral DNA polymerase, causing a
substitutionofasparagine(N)byasparticacid(D)ataminoacid
position752,issigniﬁcantlyassociatedwithoutbreaksinwhich
neurologic signs were recorded (p , 0.0001) [2].
Primary EHV-1 replication occurs in the respiratory tract,
followed by spread to regional lymphatic tissues and
dissemination via a cell-associated viremia [3,4]. In contrast
to other neuropathogenic alphaherpesviruses, which cause
encephalitis via neuronal infection, EHV-1-induced myeloen-
cephalopathy is caused by infection of vascular endothelia of
arteries supplying the central nervous system (CNS). The
subsequent inﬂammatory response leads to thrombosis and
ischemic damage [5,6]. A sustained and high-level presence of
viral DNA in the blood stream, and, by implication, cell-
associated viremia, is associated with the development of
neurologic disease in EHV-1-infected horses [7,8]. The
neurologic signs range from mild ataxia to complete para-
plegia [9,10].
We hypothesized that mutation of the pol gene of a
neuropathogenic strain to the N752 variant, which is rarely
isolated from neurologic disease outbreaks, may cause a
defect in cell-associated viremia, and, ultimately, less endo-
thelial damage in the CNS vasculature. There are several
possible mechanisms whereby Pol activity may inﬂuence the
level of viremia, including (i) altered replication levels at the
primary site of infection (respiratory epithelia), (ii) altered
transmission to or levels of replication within circulating
leukocytes, and (iii) altered efﬁciency of transmission from
leukocytes to endothelial cells.
In the studies reported here, we conﬁrmed the causal
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pathogenicity in the primary host through targeted muta-
genesis of a single nucleotide in the 150-kb DNA genome of
the virus. The implication that this mutation directly affects
the function of the Pol enzyme is further supported by our
experiments with the Pol-targeting drug aphidicolin. Our
data also indicate that the mutant and revertant viruses differ
in their tropism for lymphocyte subsets, suggesting that the
D!N752 mutation may affect replication in certain cell types.
Results/Discussion
BAC Cloning and Mutagenesis
Bacterial artiﬁcial chromosome (BAC) cloning and muta-
genesis facilitate manipulation of herpesvirus genomes [11]
and is performed in Escherichia coli. Introduction of compen-
satory mutations is rare, because mutagenesis is independent
of virus growth in eukaryotic cells [12]. Red recombination in
E. coli allows introduction of point mutations without
exogenous sequences being left behind [13]. We cloned
neuropathogenic EHV-1 strain Ab4 at passage 8 as a BAC,
via insertion of mini-F vector sequences into the nonessential
gene 71 locus. During reconstitution of wild-type virus, as
well as the mutant viruses used later in the study, gene 71 was
repaired and vector sequences removed via homologous
recombination in cells cotransfected with the EHV-1 BAC
and a plasmid containing gene 71 sequences. We veriﬁed that
the reconstituted, BAC-derived EHV-1 recombinants were
identical to the parental isolate by restriction fragment
length analyses and by Western blot analysis, which showed
expression of gp2 encoded by gene 71 (Figure 1). Pilot studies
showed that the BAC-derived and parental Ab4 viruses had
similar in vitro growth properties and virulence in the BALB/
c mouse model [14] as well as in ponies (unpublished data).
To test our hypothesis that the D752 Pol variant is
responsible for enhanced, viremia-dependent inﬂammation
of the CNS vasculature by neuropathogenic strains, we
mutated the Ab4 BAC (D752) so that it would express the
presumed non-neuropathogenic variant (N752) by two-step
Red recombination [13]. Then, the N752 mutant was used to
engineer a revertant virus (D752) by the same protocol. In all
virus-positive lymphocyte cultures isolated from infected
horses, we sequenced the region of interest in the mutant
(N752) and revertant (D752) viral genomes at each stage of
the experiment, to verify stability of the point mutation.
Recombinant Viruses Have Similar Replication
in Fibroblasts and in Mice
The D752 and N752 viruses had virtually identical single-
stepgrowthpropertiesinequineNBL-6dermal ﬁbroblastcells
(p ¼ 0.6 and 0.8 for extra- and intracellular virus yields,
respectively) at all tested time points post-infection (Figure
S1). The ratios of intracellular genome copy numbers to
plaque-forming units (PFU), averaged from samples collected
at8–36hpostinfection,were1.1310
4forthemutant,4.1310
3
for the revertant, and 2.1310
3 for the parental BAC-derived
virus (nonsigniﬁcant, p ¼ 0.3). These data demonstrate no
signiﬁcant difference resulting from pol mutation in replica-
tion properties in vitro in equine ﬁbroblasts.
The mutant N752 and revertant D752 viruses also caused
similar daily body weight loss and viremia levels in groups of
ten BALB/c mice each (Figure S2A and S2B). Six additional
mice were infected per group, were humanely killed in
the acute infection phase, and had similar viral loads in
various tissues for both groups (Figure S2C). The mouse
model of EHV-1 is a useful preliminary measure of
attenuation. However, mouse brain microvascular endothe-
lial cells are not susceptible to EHV-1, in contrast to those of
horses [15]. Furthermore, the virus does not spread between
mice, as it does in the natural host [16]. Our recovery of high
numbers of viral genome copies from the brains and spinal
cords of mice, in the absence of observable neuronal or
Figure 1. Viral Mutagenesis
(A) Genomic restriction fragment patterns of the wild-type Ab4 strain
(lane 1), the N752 mutant (lane 2), and the revertant D752 (lane 3) were
analyzed to verify that no gross rearrangements had occurred during
mutagenesis (marker, 1-kb ladder [Invitrogen]).
(B) Expression of the glycoprotein restored in place of BAC sequences
(gp2, 250 kDa, indicated by arrow) in all constructs was confirmed by
Western blot analysis, with EHV-1 strain RacL11 (with and without gp2
[29]) and the parental Ab4 BAC as controls (marker, Precision Plus [Bio-
Rad]). Mutant virus constructs were also sequenced in the region of
interest at each passage level, including after reisolation from horses.
doi:10.1371/journal.ppat.0030160.g001
PLoS Pathogens | www.plospathogens.org November 2007 | Volume 3 | Issue 11 | e160 1584
Neurovirulence of a Herpesvirus Point Mutant
Author Summary
Equid herpesvirus type 1 (EHV-1), a close relative of varicella-zoster
virus and herpes simplex virus of humans, is spread by aerosol and is
the causative agent of the most common neurologic disease of
horses. Outbreaks of the neurologic form of EHV-1 can be
devastating to individual animals and entire herds, and approx-
imately one-third of the affected horses generally are at risk of death
or suffer so extensively that euthanasia becomes necessary. Our
report provides evidence for a direct causal link between the
genotype of EHV-1 strains and their neurovirulence, and thereby
gives a long-awaited explanation for the conundrum of the different
clinical outcomes following EHV-1 infection. We proved that
alteration of one amino acid in the key viral enzyme, DNA
polymerase, which is conserved in all herpesviruses, renders the
virus unable to cause neurologic disease. The improved clinical
outcome is likely due to the reduction in virus levels in the
bloodstream, ultimately resulting in less virus reaching the central
nervous system. In summary, our study shows that herpesvirus
virulence and tissue tropism in the natural host are linked with the
function of a key virus-encoded enzyme involved in DNA replication.endothelial damage in the CNS, highlights the deﬁciency of
the mouse as a model for EHV-1 neuropathogenicity.
The N752 Mutant Is Attenuated in the Natural Host
We conducted two infection trials in the natural host, ﬁrst a
pilot study in 2-y-old Welsh mountain ponies (four per group),
and second a larger study in adult (3- to 16-y-old) mixed-breed
horses (seven per group). Animals were randomly assigned to
treatment groups and the identity of the treatments remained
concealed from the investigators throughout the studies.
In both experiments, virus was administered via the natural,
intranasal route by aerosolization.
Intheﬁrststudyinponies,clinicalsignsofupperrespiratory
tract disease, which comprised nasal discharge, coughing, and
lymph node swelling, were more severe in the D752 (neuro-
pathogenic genotype) virus group (Figure 2A). The cumulative
clinical scores of the D752 group were signiﬁcantly higher
than those of the N752 group (p ¼ 0.003). The D752 group
also displayed higher median rectal temperatures during the
ﬁrst 3 d postinfection (Figure 2C), with a signiﬁcantly longer
duration of fever (median duration of temperatures .38.5 8C:
3 d for D752 and 1 d for N752; p ¼ 0.01). Serum neutralizing
antibody titers were similar between the groups (Figure 2E).
Neurologic hind limb signs (mild ataxia) were observed in one
ponyfromtheD752groupandnonefromtheN752group,but
detailed neurological assessments were not conducted in this
study.Postmortemexamswereperformedonallponiesat14d
postinfection. No speciﬁc signs of EHV-1 related pathology
were detected in any of the ponies, but the spinal cords were
not serially sectioned and hence focal pathology may not have
been detected. Determination of viral load via quantitative
PCR (qPCR) of peripheral blood mononuclear cells (PBMCs)
demonstrated signiﬁcantly higher titers (p¼0.03) in the blood
for the D752 group, with maximum titers over 100-fold higher
than in the N752 group (Figure 3A). Viremia was detectable,
albeit at a low level, for a longer period for the N752 group,
remaining at approximately ten copies per 10
6 PBMC from
days 12–14 postinfection, a time when titers were below the
detectable threshold for the D752 group. Assessment of cell-
associated viremia by virus isolation from heparinized blood
(Figure 4A) detected viremia in all D752 ponies (median
numberof days positive:4) comparedwith onlytwoof thefour
N752 ponies (median number of days positive: 1.5). Peak levels
and the kinetics of virus shedding determined by qPCR were
similar for the two groups (Figure 3C), although on most days
Figure 2. Clinical Data from the Equine Experimental Infection Studies
Studies were conducted in a smaller pilot study (ponies) and
subsequently a larger study (horses) with the revertant pol genotype
virus (D752, ) and mutant virus (N752, *). Data were collected before
and after treatments. *p , 0.05.
(A and B) Median cumulative clinical scores, which indicate overall
symptom severity.
(C and D) Median rectal temperatures (8C), with a line drawn at the cutoff
temperature for fever (38.5 8C).
(E and F) Median serum virus neutralizing antibody titers. Data from the
first experiment on ponies (four animals/group) are shown in the left
graphs (A, C, and E), those from the second experiment on horses (seven
animals/group) in the right graphs (B, D, F).
doi:10.1371/journal.ppat.0030160.g002
Figure 3. Real-Time Quantitative PCR Data from the Equine Experimental
Infection Studies
Results from studies conducted on ponies (A and C) and horses (B and D)
withtherevertantpolgenotypevirus(D752, )andmutantvirus(N752,*).
*p , 0.05.
(A and B) Geometric means of normalized lymphocyte-associated viremia
measured by qPCR, with EHV-1 DNA copies normalized per million
cellular genomic DNA copies.
(C and D) Virus titers in nasal excretions measured by qPCR. Shown are
geometric mean normalized viral genome copies per milliliter of nasal
swab solution. Standard deviations (error bars) are plotted, but are small
compared to the y-axis scale and thus not visible for some data points.
Data from the first experiment (ponies, four animals/group) are shown in
the left graphs (A and C), those from the second experiment (horses,
seven animals/group) in the right graphs (B and D).
doi:10.1371/journal.ppat.0030160.g003
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shedding, however, were not signiﬁcant (p¼0.32).
Similar results were observed in the second study in older
horses, which was conducted with larger animal numbers. The
horses did not display the coughing or enlarged lymph nodes
apparent in the pony infection study, but were positive for
nasal discharge, with the D752 having a signiﬁcantly higher
nasal discharge severity score (p ¼ 0.01) (Figure 2B). Rectal
temperatures were also elevated for a signiﬁcantly longer
period for the D752 group (p ¼ 0.009), with a median fever
duration of 3 d for D752 and 1 d for N752 (Figure 2D). Serum
neutralizing antibody titers were higher overall in the D752
group (Figure 2F). The peak viral load determined by qPCR in
PBMC was approximately 10-fold higher for the D752 group
(Figure 3B), with signiﬁcantly higher mean titers recorded for
the D752 group from days 1–14 postinfection (p ¼ 0.01).
Assessment of viremia by virus isolation also detected a
signiﬁcant difference in viremia (p¼0.04), with a median of 3
d positive in the D752 group and 0 d in the N752 group
(Figure 4B). The peak levels and kinetics of viral DNA
secretion were similar for the two groups (overall repeated
measures p ¼ 0.3, Figure 3D). However, analysis of the
duration of nasal shedding of infectious virus using time to
event analysis indicated that the D752 group had a longer
duration (95% conﬁdence interval for median duration:
3–5 d for N752 and 5–6 d for D752; p ¼ 0.04).
The minimal infectious dose for EHV-1 is unknown, and
we therefore do not know how much virus shedding is
actually required for animal-to-animal transmission [17].
Although in both studies the titers for the D752 group were
somewhat higher than those of the N752 group on most of
the days sampled, the peak genome loads in nasal secretions
of the two groups were similar, and there was no signiﬁcant
difference in overall virus shedding (Figure 3C and 3D).
Although the duration of shedding can deﬁnitely not be
discounted, and a longer duration of shedding of infectious
virus was observed for the D752 group in the second study,
we assume that the magnitude of shedding is a more
important factor for transmission. By this measure, the two
viruses were comparable in infectivity.
We observed neurologic hind limb signs in two horses from
the D752 group (Table 1). Because assessment of neurologic
signs is a subjective parameter, neurologic exams performed
during the larger trial were digitally recorded and reviewed by
four independent equine specialists to provide diagnoses.
Combiningtheresultsfromthetwostudies,threeof11animals
Figure 4. Viral Isolation from PBMC/RK13 Coculture Experiments
Virus was isolated during the equine experimental infection studies with
the revertant pol genotype virus (D752, ) and mutant virus (N752, *).
*p , 0.05.
The number of culture-positive animals are shown, out of four total
ponies per group (A) and seven total horses per group (B).
doi:10.1371/journal.ppat.0030160.g004
Table 1. Neurologic Grades, CSF Cytology, and qPCR
Animal ID Group Days
Postinfection
Neurologic
Grade
CSF
Color
Nucleated Cells/
ll CSF
Differential Cell Count CSF Total Protein
(mg/dl)
CSF Viral Genome
Copies/ml
Reference
a N/A N/A N/A Clear ,6 No abnormalities ,100 0
4 D 7 2 Clear 5 75% lymphocytes;
25% macrophages
45 174
4 D 16 2 Yellow 56 LS; 24 AO AO: 86% lymphocytes;
14% macrophages
215 LS; 139 AO 2,821 LS; 9,450 AO
9 D 16 1 Clear 2 53% macrophages;
47% lymphocytes
67 ,5
42 D 9 0 Clear 0 No abnormalities 20 ,5
228 D 7 0 Clear 9 80% small lymphocytes;
20% macrophages;
few red blood cells
50 168
120 N 15 0 Clear 1 No abnormalities 67 ,5
263 N 15 0 Clear 9 70% lymphocytes;
29% macrophages;
1% neutrophils
73 100
263 N 19 0 Light yellow 13 LS: 52% lymphocytes;
40% macrophages;
8% neutrophils
233 120 LS; ,5A O
Xanthochromia, elevated nucleated cell count, and elevated protein levels are typical (but not specific) for EHV-1 myeloencephalopathy [38]. Samples were collected from the lumbosacral
(LS) space in the standing horse, and additional postmortem samples were collected from the atlantooccipital (AO) space. The four veterinarian reviewers’ consensus hind limb neurologic
grades are reported according to the scale from Mayhew et al. [39], with a grade 2 representing moderate pelvic limb signs, grade 1 representing mild signs, and grade 0 within normal
limits. Grades for horses not listed in this table were zero.
aReference values for CSF fluid provided are according to Mayhew et al. [40].
N/A, not applicable.
doi:10.1371/journal.ppat.0030160.t001
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none of the 11 in the N752 group, although the difference in
scores between the two groups was not signiﬁcant (p ¼ 0.06).
We sampled and analyzed cerebrospinal ﬂuid (CSF) to corrob-
orate clinical observations. Figure 5B and Table 1 show data
from CSF samples. Horse D752–4 was diagnosed with a neuro-
logic grade of 2 (moderate hind limb ataxia; all four clinicians
were in agreement), and horse N752–263 had no neurologic
abnormalities.However,bothhorseshadelevatednucleatedcell
counts and protein levels, indicative of inﬂammation (Table 1).
Horse D752–4 had a CSF EHV-1 load two orders of magnitude
higher than that of horse N752–263 (Table 1).
Complete postmortem examinations on horses D752–4
(10-y-old female) and N752–263 (12-y-old castrated male) were
conducted. Histological lesions in horse D752–4 were present
throughout the meninges, but were most frequent and more
severeintissuesoverlyingthecaudalhalfofthethoraciccordas
well as the cranial portion of the lumbar cord (Figure 5D–5F).
Meninges showed moderate inﬁltration by lymphocytes,
plasma cells, and scattered neutrophils, as well as substantial
perivascular cufﬁng. Throughout the sections, veins and
venules were dilated, congested, and lined by reactive
endothelial cells. The spinal cord itself was largely unaffected,
with the exception of two small perivascular lymphocyte cuffs
andafocusofaxonalswellinganddilatedmyelinsheathsinthe
whitematter.Incontrast,noCNSlesionswerepresentinhorse
N752–263, which had the most severe illness among the horses
in the mutant group (Figure 5C).
To conﬁrm EHV-1 presence and to quantify viral load in
tissues, we performed qPCR on a panel of lymphatic and
CNS tissues collected postmortem (Figure 5A). Horse D752–4
had the highest viral load in the spinal cord at the L1
vertebral space. It also had EHV-1 genome copies in the
brain, lung, and lymph nodes. In stark contrast, only tissue
samples from two of the lymph nodes from horse N752–263
were qPCR-positive (Figure 5A).
The D752 Neuropathogenic Virus Infects
CD4
þ Lymphocytes Preferentially
A reduction in cell-associated viremia may link viral
replication and CNS inﬂammation [2]. We hypothesized that
variation of the pol sequence may affect replication of EHV-1
in leukocytes. The horse experiment demonstrated this
connection, particularly in the case of cells from CSF of horse
D752–4, which typically exhibited cytoplasmic granules. This
observationsuggestedtheinvolvementofcellswithacytotoxic
and/ornaturalkillerphenotypeintheinﬂammationwithinthe
spinal cord (Figure 5B). Therefore, we further hypothesized
that the N752 mutant virus, in contrast to the D752 virus, may
preferentiallyreplicateorspreadincertaincelltypessuchasB
cells or monocytes. We tested the hypothesis by infecting
equine PBMCs in vitro with N752 or D752 viruses expressing
enhanced green ﬂuorescent protein (EGFP), and analyzing
thesecells by ﬂow cytometry (Figure 6). When compared to the
N752 mutant virus, D752 virus preferentially infected CD4
þ
cells (p ¼ 0.04). There was a similar trend for increased D752
infection in CD8
þ cells, but differences were nonsigniﬁcant
(p ¼ 0.12). Monocytes (CD14-positive) and B cells, however,
showed the opposite trend (p ¼ 0.06 for CD14 and 0.12 for
B cells), as demonstrated by preferential infection of N752 in
these subpopulations. These data suggest that the neuro-
pathogenic variant has an enhanced tropism for the equine
CD4
þT cell subpopulation invitro.Further studiesare needed
to determine whether altered tropism for lymphocyte subsets
is a major contributor to the more robust replication of D752
viruses observed in vivo, evidenced by higher levels of viremia
(Figures 3A, 3B, and 4) and increased virus neutralizing
antibody titers (Figure 2F). In particular, it will be important
to compare the replication properties of the D752 and N752
recombinants in a variety of (primary) equine cell types.
Increased Sensitivity to Aphidicolin of the N752 Virus
and Polymerase Variant
The availability of polymerase-acting drugs provided the
opportunity to investigate whether functional differences in
vitro between the two EHV-1 Pol variants might exist and
provide additional insight into the mechanism(s) underlying
Figure 5. Postmortem Examination of Horses Infected with N752
or D752 Viruses
(A) Normalized viral genome load in tissues collected from horses
examined postmortem: N752–263 of the mutant group, with only two
tissues positive for viral genome copies (&) and D752–4 of the revertant
group (“), with multiple positive tissues throughout the CNS and
lymphatic system. RTG, right trigeminal ganglion; RLN, retropharyngeal
lymph node; BLN, bronchial lymph node; SMLN submandibular lymph
node.
(B) Representative photomicrograph of lymphocytes present in the CSF
of horse D752–4, with red cytoplasmic granules typical of cytotoxic T
cells or natural killer cells.
(C) Representative hematoxylin and eosin-stained section of caudal
thoracic spinal cord tissue from horse N752–263 (bar 700 lm) showing
no abnormalities.
(D and F) Representative caudal thoracic cord sections from horse D752–
4 (bars indicate, respectively, 1 mm, 40 lm, and 40 lm) showing
lymphocytic cuffing in the meninges (D), dilated myelin sheaths with
swollen axons, surrounded by reactive mononuclear cells (E), and typical
lymphocytic perivascular cuffing (F).
doi:10.1371/journal.ppat.0030160.g005
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human herpesvirus Pol mutants that exhibit altered sensi-
tivity to drugs mimicking and/or competing with the natural
substrates have helped to delineate enzyme regions and even
single amino acid residues involved in catalysis and/or
substrate binding [18]. The drug aphidicolin competitively
inhibits the binding of certain deoxyribonucleoside triphos-
phates (dNTPs) to family B DNA polymerases, which include
herpesvirus polymerases [19]. We performed virus yield
titration and qPCR assays to evaluate the sensitivity in vitro
of both the mutant N752 (non-neuropathogenic) and the
revertant D752 (neuropathogenic) virus to aphidicolin. The
N752 mutant virus was signiﬁcantly more susceptible to the
drug than the D752 revertant virus, with a reduction in 50%
inhibitory concentration (IC50) of 33% (from 0.06 to 0.04 lM,
p¼0.02) in virus yield titration assays (Figure 7A) and of 28%
(from 0.07 to 0.05 lM, p , 0.0001) in qPCR assays (Figure 7B).
To investigate whether the observed differences in sensi-
tivity to aphidicolin could be related to functional differences
between the D752 and N752 Pol variants, we examined the
DNA polymerase activity in vitro of both proteins in the
absence or presence of the drug. As is the case in all
herpesviruses studied to date, an accessory protein, EHV-1
pORF18, which stimulates nucleotide incorporation by Pol,
formstheviralDNApolymeraseholoenzyme togetherwiththe
Figure 6. Equine PBMC Infection In Vitro
(A) Each point represents the percentage of virus-infected cells that were
positive for the respective equine cellular marker in an individual horse,
as measured by FACS at 48 h postinfection. Cells were infected with
either the neuropathogenic D752 revertant ( ) or the non-neuro-
pathogenic N752 mutant (*) virus; dark lines show median percentages
for the revertant D752 group, and grey lines median percentages for the
N752 mutant group.
(B) Paired differences between the two viruses (percentage of infected
cells expressing the respective cellular marker: N752 minus D752 for each
individual horse) are plotted. The efficiency of PBMC infection ranged
from 10% to 30%.
doi:10.1371/journal.ppat.0030160.g006
Figure 7. Differential Sensitivity of the Pol D/N752 Virus and Protein
VariantstoAphidicolinandStructuralModelingofthePolRegionofInterest
(A) Cells were infected with the Pol D752 revertant ( ) or N752 mutant
(*) virus, treated with aphidicolin, incubated 3 d, then lysed; final virus
yield was titrated on new cells.
(B) DNA was also extracted after the lysing step and qPCR performed to
quantify normalized viral genome copies.
(C) The DNA polymerase activity of Pol D752 and Pol N752 proteins, in
the absence and in the presence of pORF18 (Pol accessory subunit), was
analyzed by measuring the incorporation of [
3H]dTTP into a poly(dA)-
oligo(dT) template. (“) Pol D752; (&) Pol N752; ( ) Pol D752þpORF18;
(*) Pol N752 þ pORF18.
(D) Theeffect of aphidicolinon polymerase activityof Pol D752 ( ) and of
PolN752(*)wasassayedbymeasuringtheincorporationof[
3H]dTTPinto
apoly(dA)-oligo(dT)templateinthepresenceofpORF18.Graphsshowthe
average of three experiments with standard deviations (error bars).
Asterisk * indicates p , 0.05.
(E) Ribbon diagram of EHV-1 Pol N752 is based on HSV-1 Pol crystal
structure [23].
(F) Space-filling diagram highlights the region between HSV-1 Pol
secondary structure elements P3 and PB on the outside surface of the
palm domain.
(G) Prediction of structural changes caused by the residue variation in Pol
N752 as opposed to Pol D752.
doi:10.1371/journal.ppat.0030160.g007
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activities of Pol D752 and Pol N752 in the absence or presence
of pORF18 under different assay conditions (Figure 7C).
Nosigniﬁcant differencesbetween the polymerase activities of
Pol D752 and Pol N752, either in the absence (p ¼ 0.85) or
presence (p ¼ 0.39) of pORF18, were observed. These results
are consistent with the lack of differences in replication
properties between the mutant N752 and the revertant D752
viruses seen in tissue culture experiments (Figure S1). We then
investigated the in vitro effects of aphidicolin on polymerase
activity of the two Pol variants. Pol N752 appeared more
sensitive to aphidicolin than Pol D752 (Figure 7D), with an
IC50 value of 0.9 versus 3.1 lM( p ¼ 0.01). Again, these data
agree with those obtained in cell culture (Figure 7A and 7B),
although, in those experiments, differences in aphidicolin
sensitivity were detected at lower drug concentrations. The
differences in IC50 values between cell culture and DNA
polymerase assays, which had also been observed in the case of
a related herpesvirus Pol [21], may reﬂect the fact that
multiple rounds of virus DNA replication in culture may help
amplify aphidicolin’s inhibitory effects.
Todate, incontrasttoa numberof crystalstructuresof both
prokaryotic and eukaryotic DNA polymerases (for a review see
[22]), only one herpesvirus Pol structure has been reported,
that of herpes simplex virus type 1 (HSV-1) [23]. The EHV-1
Pol variant amino acid (D/N752) is homologous to HSV-1 Pol
residue D751. This position is located between highly
conserved Pol regions II and VI [24], immediately following
conservedmotifA,whichformsaportionofthedNTPbinding
cleft within the active site [23,25]. Structurally, this residue is
on the outside of the palm domain (Figure 7E–7G), which
houses part of the catalytic site of family B polymerases (e.g.,
eukaryotic Pol a and herpesvirus Pols) as well as that of family
A polymerases (e.g., prokaryotic Pol I) [22]. Interestingly,
conserved acidic (Asp and Glu) residues, found in close
proximity to residue 752, have been identiﬁed in family B
polymerases and are involved in metal-mediated interactions
with the incoming dNTP [26]. We consider it likely that Pol
residue 752 plays an important direct or indirect role in
substrate binding and/or catalysis. This is because of (i) the
high degree of conservation of an acidic residue (D or E) at the
position equivalent to amino acid 752 of EHV-1 Pol in all
herpesviruses [2], and (ii) the altered sensitivity to aphidicolin
of the N752 variant when compared to D752 (Figure 7A–7D).
Alternatively, the D to N change at position 752 might affect
interaction(s) of residue 752 with amino acids involved in drug
binding and catalysis by modifying Pol tertiary structure, and
thereby result in altered drug sensitivity. The differences
observed in structure predictions of the two Pol variant
proteins (Figure 7G) lend support to this hypothesis. Subtle
differences between the Pol enzyme variants in substrate
binding and catalytic activity, not evident in rapidly dividing
cell cultures in vitro, might become relevant in certain cell
types in vivo, and thus inﬂuence the efﬁciency of lytic virus
replication and/or virus reactivation from latency.
Conclusions
The results of our experimental infection studies demon-
strate that the N752 sequence variant of EHV-1 DNA Pol,
when compared to the D752 variant, has reduced overall
pathogenic potential and capacity to induce neurological
signs. This reduced virulence is associated with lower levels of
viremia, which is consistent with a previous study of EHV-1
ﬁeld isolates suggesting that neuropathogenic strains exhibit
higher levels of viremia [8]. Our study provides the evidence
that DNA Pol sequence variation by itself has a signiﬁcant
effect on the overall level of viremia.
Leukocyte-associated EHV-1 viremia is believed to be an
important aspect of the progression of infection to myeloen-
cephalopathy, which is initiated by virus transfer from PBMCs
to endothelia, relatively uninhibited by virus neutralizing
antibodies. Following endothelial cell infection, inﬂammatory
responses result in thromboischemic damage of neuronal
tissue with neurological sequelae. We hypothesize that the D/
N752 Pol sequence variation has a direct effect upon virus
replication in certain cell types in vivo relevant to the
development of cell-associated viremia. The demonstration
of a subtle alteration of Pol activity, albeit apparent only as an
altered sensitivity to the DNA Pol-targeting drug aphidicolin,
is consistent with this hypothesis. Further studies are
required to verify D/N752-related cell type-speciﬁc replica-
tion differences, but our studies demonstrating differences in
relative efﬁciency of infection of different lymphocyte
subsets in vitro, with D752 viruses having a preference for
CD4
þ T lymphocytes, may be relevant to the pathogenic
potential of EHV-1, since these cells play key roles as virus
carriers in the lytic and latent phase of the infection and in
the inﬂammatory responses that result in EHV-1 disease.
Speculation as to the evolutionary origin of the D/N752
sequence variation for EHV-1 has been discussed previously
[2]. In particular, the observation that all other herpesvirus
polymerase sequences encode an acidic residue, generally
aspartate, at the equivalent position to EHV-1 Pol 752,
suggests strongly that the N752 variant arose from a D752
progenitor. Our estimate of the prevalence of the two Pol
genotypes suggests that the majority (.75%) of EHV-1 strains
encode N752 (unpublished data). Taken together, this in-
formation suggests that the N752 variant may have a selective
advantage over D752, or at least no substantial disadvantage,
for long-term maintenance within the equine population.
From our data it is reasonable to assume, therefore, that
N752viruses do nothave a major defectintransmission. In the
pony and even more so in the horse experiment, a more
prolonged shedding of infectious virus for D752 than N752
was evident, which may potentially result in animals infected
with D752 having a longer infectious period. It may be that the
mucosal and systemic cellular immune response to N752 is
more effective than that to D752, resulting in a shorter period
of shedding. The observation of differences in the phenotype
of leukocytes infected and the capacity of virus to replicate in
these subpopulations suggest that further characterization of
the cellular immune responses to these variants is worthwhile.
However, the N752 virus was found to be shed in nasal
secretions at levels similar to those of the D752 variant during
the ﬁrst 2 d postinfection, suggesting that initial rates of
replication in the respiratory tract are similar. Since this
period marks the peak titer of EHV-1 shedding, we postulate
that the D/N752 variation has little effect, if any, on trans-
mission when infected horses are likely to be at their most
infectious. These results suggest that the N752 variant exhibits
decreased disease severity and mortality without a substantial
reduction of virus shedding and transmission, consistent with
its higher prevalence. Other scenarios that might inﬂuence
survival of either sequence variant in the population, such as
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latency, are also conceivable, but remain to be tested.
In summary, we demonstrated that a naturally occurring
variation in a single amino acid position of the viral DNA
polymerase is responsible for differing pathogenic potential
of a herpesvirus. In recent years, an increase in neuro-
pathogenic outbreaks of EHV-1 has been reported, partic-
ularly in the US, although it is still controversial as to
whether the increase is real or perceived due to heightened
awareness. The conﬁrmation that the EHV-1 Pol D/N752
sequence variation is directly associated with differences in
pathogenic potential of individual virus strains provides a
rationale for ongoing epidemiological studies, such as
monitoring the current and past prevalence of the N752
and D752 genotypes. Such analyses will allow an adequate
assessment of the risk of neurologic EHV-1 disease and help
in designing efﬁcient preventive and therapeutic measures
for the most prevalent neurologic disease of horses.
Materials and Methods
Viral cloning and mutagenesis. EHV-1 strain Ab4 (GB80_1_2
isolated from a quadriplegic mare [27]) was cloned as a BAC by
cotransfection of a mini-F plasmid with wild-type genomic DNA in
rabbit kidney RK13 cells, as described previously [28]. Brieﬂy, the
mini-F bacterial origin of replication sequence pHA2 containing a
chloramphenicol resistance gene (cat) and the egfp gene were cloned
into a transfer plasmid and introduced in lieu of nonessential gene 71
(encoding glycoprotein gp2 of EHV-1) by homologous recombination
in RK13 cells [29]. The BAC was maintained in E. coli EL250 cells,
which harbor the recombination system of phage k under the control
of a temperature-sensitive repressor [30]. The BAC was mutated to
the opposite Pol genotype (N752) by converting nucleotide number
2254 of pol (ORF30) from a guanine to an adenine (see Table S1 for
primers) using two-step Red-mediated en passant recombination [13].
Following conﬁrmation of the respective genotypes by nucleotide
sequencing (see Table S1 for primers), repaired virus was produced
by cotransfection of a plasmid encoding EHV-1 Ab4 gene 71 with
DNA of the respective mutant BAC. Resultant GFP-negative viruses,
lacking the BAC cassette, were fully restored in gp2 expression, and
exhibited restriction enzyme patterns identical to those of the
parental Ab4 virus (Figure 1).
Virus culture. High-titer stocks of each virus were produced by
passaging the transfection product once on equine NBL-6 cells in
Eagle’s minimal essential medium (EMEM) supplemented with 20%
fetal bovine serum (FBS). Infected cells were frozen/thawed twice
( 80 8C/37 8C), centrifuged for 5 min at 4,500g, supernatants were
collected and stored at  80 8C. Titration of the virus suspension was
performed on RK13 cells [29].
DNA polymerase assays. The pTM1-ORF30 plasmid, which ex-
presses Pol (D752 variant) of EHV-1 Ab4 under a T7 promoter, was
previously described [20]. The pTM1-ORF30 N752 plasmid harboring
the pol N752 mutant was created using the Quick-Change Mutagenesis
kit (Stratagene, La Jolla, CA), amplifying the pTM1-ORF30 plasmid
with primers listed in Table S1 pTM1-ORF30_D752N_F (forward)
and pTM1-ORF30_D752N_R (reverse). The mutated pol N752 gene
was completely sequenced and shown to contain only wild-type
sequences except for the engineered point mutation.
In vitro transcription-translation of the pol D752 and pol N752
genes was performed from plasmid pTM1-ORF30 or pTM1-ORF30
N752 using the TNT T7 coupled reticulocyte lysate system from
Promega (Madison, WI) according to the manufacturer’s guidelines.
To examine protein expression levels, the translation products were
labeled with [
35S]methionine (Perkin Elmer, Waltham, MA) and
analyzed by sodium dodecyl sulfate-7.5% polyacrylamide gel electro-
phoresis (SDS-PAGE) and autoradiography. Puriﬁed baculovirus-
expressed pORF18, the accessory subunit of EHV-1 DNA polymerase,
was prepared as described previously [20].
Basal DNA polymerase activity of Pol D752 and of Pol N752 and
stimulation of their activity by pORF18 were assayed by measuring
the incorporation of [
3H]dTTP (Amersham Bioscience-GE Health-
care, Milan, Italy) into a poly(dA)-oligo(dT) template (Amersham
Bioscience-GE Healthcare) as previously reported [20], using 12 llo f
in vitro transcribed-translated Pol D752 or Pol N752 in the absence
or in the presence of 600 fmol of puriﬁed baculovirus-expressed
pORF18 in a 60-ll reaction volume.
The effect of aphidicolin on Pol activity was tested in similar assays,
with 4 ll of in vitro-transcribed and -translated Pol D752 or Pol N752
plus 200 fmol of pORF18 in the presence or absence of various
amounts of drug in a 20-ll reaction volume. Aphidicolin (Sigma-
Aldrich, St. Louis, MO) was dissolved at a 300 lM concentration in
10% DMSO. In these assays, the ﬁnal concentration of compound-
derived DMSO was maintained at 0.5% (vol/vol) in all samples. In
control samples with no drug added, a corresponding volume of pure
DMSO was added to reach a ﬁnal concentration of 0.5%.
Viral drug sensitivity assays. Aphidicolin (Calbiochem, San Diego,
CA) was dissolved as a 1 mg/ml (2.95 mM) stock in DMSO, then serially
diluted in EMEM supplemented with 0.5% FBS. For virus yield
titration and qPCR assays, RK13 cells were plated at 2310
5 cells/ml in
24- and 96-well plates (BD Falcon, San Jose, CA), allowed to adhere
overnight, and infected with N752 mutant or D752 revertant virus at
a multiplicity of infection (MOI) of 0.01. After virus adsorption for
2 h at 37 8C, cells were washed twice with PBS and incubated with 1 ml
(for virus yield titration assays) or 200 ll (for qPCR assays) of fresh
media containing aphidicolin at various concentrations. Each ﬁnal
drug concentration was tested in three independent wells. The ﬁnal
concentration of the DMSO vehicle was less than 0.04 % (vol/vol).
Plates were incubated for 2 d at 37 8C and then subjected to two
freeze-thaw cycles ( 80 8C and 37 8C). Virus yield titers were
determined by transferring 100 ll aliquots from each of the wells
to a fresh 24-well monolayer culture of RK13 cells followed by 1:10
serial dilution across the plate. Cultures were incubated for 3 d, then
cells were stained, and the numbers of plaques were counted. Viral
DNA genome copies were quantitated by qPCR as described below,
using the cellular 18S rRNA gene for normalization.
In vitro PBMC infection assay. PBMC were isolated by density
gradient centrifugation over Histopaque 1077 (Sigma-Aldrich) from
buffycoatsof30mlofheparinizedbloodcollectedfromhealthyhorses
(approximate ages 10–29 y) with no history of ongoing or previous
EHV-1 infection. Four experiments were conducted, each using blood
from a different donor horse. Cells were infected immediately after
isolation at an MOI of 1 using the GFP-expressing, reconstituted BAC
clones of the Pol mutant (N752) and revertant (D752) viruses, and
incubated for 48 h in conical polypropylene tubes (BD Falcon). Cell
populations were characterized with a Becton Dickinson FACScalibur
after immunoﬂuorescentstaining usingmousemonoclonalantibodies
recognizing either equine CD4 (clone CVS4, Abd-Serotec, Raleigh,
NC), CD8 (clone 73/6.9.1, VMRD, Pullman, WA), or CD14 (clone 105,
kindly provided by Dr. Bettina Wagner, Cornell University, Ithaca,
NY), and a secondary Cy5-labeled anti-mouse antibody (Jackson
ImmunoResearch, West Grove, PA), or a Cy5-conjugated goat-anti-
horse B cell antiserum (kindly provided by Dr. Bettina Wagner).
Animal experiments. The mouse and horse experiments were
performed with approval of the Cornell University Institutional
Animal Care and Use Committee. The pony experiment performed in
Newmarket (UK) was approved by the UK Home Ofﬁce. All treatment
administration, sample and data collection, clinical examinations,
and statistical analyses for these studies were performed with the
identity of the treatment concealed from the investigators.
BALB/c mice (n ¼ 16 per group) were anesthetized with intra-
peritoneal xylazine/ketamine and inoculated intranasally with 1310
5
PFUofvirussuspendedin25llofEMEM,or25llofuninfectedNBL-6
cell supernatant for the placebo group. Body weights were recorded
daily and mean daily percentage body weight loss was compared
between groups.Approximately 100llofbloodwascollectedfromten
mice per group at days 2, 6, and 9 postinfection by submandibular
venipuncture, diluted to 200 ll with sterile 13PBS containing 100 mM
EDTA, and frozen at  80 8C. On days 3 and 5, three mice from each
group were humanely killed by CO2 inhalation. Lungs, spleen, brain,
and the upper 3–4 cervical vertebrae were collected using sterile
procedures. Half of each organ was ﬁxed in formalin for histopathol-
ogy and immunohistochemistry; the other half was immediately
frozen. DNA was puriﬁed in parallel with frozen blood samples using
the DNeasy 96 Blood/Tissue kit (Qiagen, Valencia, CA).
Two independent equine infection experiments were performed.
Both experiments tested the same BAC-derived mutant (N752) and
revertant (D752) viruses. All animals enrolled had paired serum virus
neutralizing antibody titers ,1:32 (horses), or paired complement
ﬁxing antibody titers ,1:10 (ponies) and were randomized to
treatment groups. Starting 2 d prior to infection and for the
duration of the experiment, animals were monitored daily for rectal
temperature, nasal discharge, coughing, SMLN swelling, and neuro-
logic signs. Cumulative clinical scores were calculated as follows: 1
point for serous nasal discharge, or 2 points for mucopurulent or
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points for frequent coughing; 1 point for SMLN swelling; 1 point for
respiratory rate . 30, or 2 points for respiratory rate . 50.
Blood was collected daily in heparinized Vacutainers (Becton-
Dickinson, San Jose, CA). Each buffy coat from two heparinized blood
tubes was layered onto a gradient of Histopaque 1077 and 1119 for
isolation of viable PBMCs as recommended by the supplier (Sigma
procedure 1119). Serum from coagulated blood drawn at weekly
intervalswas assayedfor viral neutralization by a veterinary diagnostic
laboratory. Nasal swabs were also collected daily, by simultaneously
inserting two 15-cm polyester-tipped swabs (Fisher Scientiﬁc, Pitts-
burgh, PA) into the ventral meatus of one nostril. The samples were
immediately placedin 2 mlof viraltransportmedia:10%neonatalcalf
serum in phosphate-buffered saline, containing 33 antibiotic-anti-
mycotic (Gemini BioProducts, Woodland, CA): 300 U/ml penicillin,
300 lg/ml streptomycin, 0.75 lg/ml fungizone; and 68 lg/ml
enroﬂoxacin (Bayer Animal Health, Shawnee Mission, KS). Swabs
were then incubated on ice for 2–4 h. For viral isolation, 200 ll of the
nasal swab solution was diluted in EMEM (supplemented with 10%
FCS and 33 antibiotic-antimycotic) and titrated on conﬂuent
monolayers of RK13 cells. After 2 h, the medium was replaced with
0.8% methylcellulose dissolved in the same growth medium. Plates
were read 3 d postinoculation after acetone ﬁxation and crystal violet
staining. Results were recorded as titers of PFU per milliliter of
inoculate. Another 200 ll of nasal swab solution was frozen at 80 8C
and later thawed for DNA extraction as described below.
In the ﬁrst equine experiment, two groups of four Welsh Mountain
ponies, all 2-y-old females, were infected while housed in a BSL-3
facility in Newmarket, UK. Each group was in a separate room under
negative air pressure with its own air supply. Each pony was given
1 3 10
7 TCID50 (approximately 7 3 10
6 PFU) of aerosolized virus, as
described previously [31]. A second equine challenge experiment was
performedatCornellUniversity,Ithaca,NY.Twogroupsofsevenadult,
mixed-breed horses, aged 3–16 y, were infected with 1 3 10
7 PFU of
aerosolized virus while housed in individual BSL-2 rooms as described
previously[7].Ageswerenormallydistributedwithineachgroup,witha
mean of 8 y in the D752 group and 10 y in the N752 group. Each group
had ﬁve females and two castrated males. Horses were kept inside the
rooms until virus could no longer be cultured from nasal swabs, then
were led outside daily for neurologic exams. Under sedation with
detomidine (Pﬁzer Animal Health, Exton, PA) at 0.01 mg/kg, CSF was
collected aseptically as deemed necessary using a 5-in 18 gauge spinal
needleinthelumbosacral space.CSF wasalsocollectedpostmortemin
the atlanto-occipital joint space from humanely killed horses. At
necropsy,tissuesfromallmajororgansincludingbrainandspinalcord
werecollected.SteriletissuesamplesforqPCRweretaken,immediately
frozen at 80 8C, and processed as described below. CNS tissues were
ﬁxedinneutralbufferedformalinasawholeandgrossexaminationwas
completed after the tissues were fully permeated by the preservative.
Aftergrossexaminationwascompleted,representativesectionsofCNS
tissue were processed for histopathology.
Real-time quantitative PCR. Aliquots of 5 3 10
6 PBMC, 200 llo f
nasal swab, and postmortem tissues were processed with the
QIAamp96 DNA blood/tissue kit (Qiagen), with a ﬁnal DNA elution
volume of 200 ll. qPCR was performed using the 7500-FAST real-
time PCR system (Applied Biosystems, Foster City, CA) with reaction
mixtures containing TaqMan Fast Universal PCR Master Mix, 900 nM
primers, 250 nM probe, and 5 ll of DNA sample, in a 20 ll total
volume. The thermal cycling program was: 20 s at 95 8C, followed by
40 cycles of 95 8C for 3 s and 60 8C for 30 s. Each sample was run in
triplicate. All normalized viral genome copy numbers for animal
samples were calculated by the relative standard curve method, with
the BAC clone of Ab4 used as a viral standard, a BAC clone of equine
chromosome ECA1 for horse genome copy quantiﬁcation (kindly
provided by Drs. R. Tallmadge and D. Antczak [32]), and a partial
clone of the murine iNOS (inducible nitric oxide synthase) gene for
mouse genome quantiﬁcation. A Taqman assay for the EHV-1 IR6
gene was used to quantify viral genome copies [7]. Taqman genomic
normalization assays were designed for the mouse iNOS gene or the
horse b2-microglobulin gene, b2-M (Table S1). Normalization of viral
DNA yield from nasal swabs was performed by addition of 5 3 10
3
copies of Marek’s disease virus (MDV) BAC clone pRB-1B [33] to the
lysis buffer during DNA puriﬁcation, and detecting copies of MDV
gD [34]. Puriﬁcation efﬁciency of nasal swabs was controlled by
dividing each copy number result by the mean number of copies in all
samples. Relative quantiﬁcation of EHV-1 genome copies in the drug
sensitivity experiment was performed using the DDCT method [35],
with the 18S rRNA gene as the endogenous control, and the
untreated, infected well as the calibrator.
Statistics. Statistical analyses were performed using SAS v 9.1 (SAS
Institute, Cary, NC). The signiﬁcance level for all experiments was set
at a¼0.05. Animal experiment data were ﬁtted to linear models using
PROC MIXED including appropriate two-way interactions, after
verifying that residuals were normally distributed. Repeated ANOVA
tests were performed for all experiments involving repeated sampling
or repeated measurements. Signiﬁcance of results was assessed at the
pair-wise level using Bonferroni t-tests with a ¼ 0.05. Data that did
not pass a Shapiro-Wilks test for normal distribution of data are
represented in ﬁgures in the form of medians or individual points.
Summary values were analyzed by Kruskal-Wallis testing. These
values included: neurologic status (assessed as the highest score per
horse), duration of fever (number of consecutive days of rectal
temperature above 38.5 8C as measured each morning), and duration
of infectious nasal shedding (number of days from the ﬁrst to the last
day of positive viral culture). Kaplan-Meier scores and p values for
nasal shedding duration were calculated using PROC LIFETEST.
In vitro FACS raw data analysis was performed with FlowJo v. 7.2
(Tree Star, Ashland, OR), using the histogram function to measure the
percent of infected cells expressing each cellular marker. Differences
between virus treatments for PBMCs from different horses were
tested for normality using the Shapiro-Wilks test, then compared to
the null hypothesis of being equal to zero with a t-test. Differences
between values in the in vitro aphidicolin sensitivityexperiments were
tested with a one-way ANOVA. IC50 values for the drug sensitivity
assay were calculated based on linear regression model ﬁt equations.
Structure predictions. Structure predictions were made based on
the HSV-1 Pol crystal structure of Liu et al. as a template ([23], Protein
Data Bank number 2GV9). The SwissProt accession numbers Q6S6P1
and P28858 were used for modeling Pol N752 and D752, respectively.
The software program SWISS-MODEL (http://swissmodel.expasy.org/
SWISS-MODEL.html) was used to make the diagrams [36]. In the
surface rendering diagram, the solvent-accessible surface is blue and
surface-exposed residues are red. All diagrams show the protein in
the same orientation (annotated in Figure 7E).
Supporting Information
Figure S1. Single-Step Growth Kinetics of D752 Revertant, N752
Mutant, and Parental D752 Ab4 Viruses in Equine Dermal Fibroblast
NBL-6 Cells
Found at doi:10.1371/journal.ppat.0030160.sg001 (5.0 MB PDF).
Figure S2. Comparison of Weight Loss, Viremia, and Viral Load in
Tissues of BALB/c Mice Challenged Intranasally with 10
5 PFU of N752
Mutant,D752 Revertant, Wild-TypeAb4 (wt) Virus,or Placebo (CTRL)
Found at doi:10.1371/journal.ppat.0030160.sg002 (544 KB PDF).
Table S1. Oligonucleotides Used in This Study
Found at doi:10.1371/journal.ppat.0030160.st001 (12 KB PDF).
Accession Numbers
The ORF30 (pol) sequence of the parental Ab4 virus is identical
to that of GenBank (http://www.ncbi.nlm.nih.gov/) accession number
AY665713. The structure predictions are based on SwissProt
(http://www.expasy.org/sprot/) Q6S6P1 (N752) and P28858 (D752),
using Protein Data Bank 2GV9 as a template.
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